New documents give insight into Luigi Mangione's state of mind in the months leading up to the murder of UnitedHealthCare's CEO
Diary entries written by Luigi Mangione reveal the now 27-year-old's detailed thinking ahead of the alleged killing of UnitedHealthcare CEO Brian Thompson last year, a new court filing shows.
A red notebook was recovered by police at the time of his December 9 arrest at a McDonald's in Altoona, Pennsylvania. In diary writings contained in that notebook, Mangione vents about his frustrations with the health insurance industry and his intent to carry out an attack. The entries also shed light on Mangione's focus on the court of public opinion and how he intended to gain widespread support through the alleged killing.
The new filing from the Manhattan District Attorney's Office is a response to a motion filed last month by Mangione's defense team seeking to stay or dismiss the New York case against him. Mangione has pleaded not guilty to all federal and state charges against him.
In August 2024, roughly four months before he allegedly shot and killed Thompson in midtown Manhattan, Mangione wrote in his diary: 'I finally feel confident about what I will do. The details are coming together. And I don't feel any doubt about whether it's right/justified. I'm glad-in a way-that I've procrastinated bc it allowed me to learn more about [UnitedHealthcare].'
'The target is insurance. It checks every box,' he continued in the August 15 entry.
That summer, Mangione – who had an active social media presence for years – appeared to stop posting online, prompting worried messages from some of his friends.
In October, another diary entry reads, '1.5 months. The investor conference is a true windfall. It embodies everything wrong with our health system, and-most importantly-the message becomes self-evident. The problem with most revolutionary acts is that the message is lost on normies.' He then goes on to explain his reasoning for not targeting the health care industry through a bombing, writing that 'innocent' lives would be unaffected by his attack.
At the time of that writing, Mangione – the privileged scion of a well-to-do family, high school valedictorian and Ivy League graduate – had reportedly vanished from view of his loved ones.
'Nobody has heard from you in months, and apparently your family is looking for you,' one user posted on X in October, tagging an account belonging to Mangione. 'I don't know if you are okay,' another posted.
Mangione allegedly gunned down Thompson on a busy sidewalk as Thompson walked toward a Manhattan hotel hosting his company's investors' conference, authorities said. The suspect appeared to be driven by anger against the health insurance industry and against 'corporate greed' as a whole, according to an NYPD intelligence report obtained by CNN.
The previously unreported writings lay bare Mangione's plans to target the insurance industry. Prosecutors argue in the filing that his actions motivated a barrage of threats against health insurance workers and made them worry for their safety.
CNN has reached out to Mangione's attorneys for comment.
In the months since the fatal shooting of Thompson, Mangione has become a cult-like figure. There has been a massive outpouring of support on social media and at his court appearances from people with deep frustration and anger at the American for-profit health care system. They see the American health insurance industry as broken, overly expensive and quick to deny coverage.
The majority of insured US adults had at least one issue with their health insurance within the span of a year, including denial of claims, according to a survey released in June 2023 by nonprofit health policy research group KFF. A legal defense fund in support of Mangione has raised more than $1 million as of Wednesday.
In the diary entries, Mangione – who allegedly used a ghost gun to carry out the killing of Thompson – criticizes bombers: 'They commit an atrocity whose horror either outweighs the impact of their message, or whose distance from their message prevents normies from connecting the dots.'
In the October 22 entry, Mangione went on to ask, 'Do you bomb the HQ? No. Bombs=terrorism. Such actions appear the unjustified anger of someone who simply got sick/had bad luck and took their frustration out on the insurance industry, while recklessly endangering countless employees.'
Instead of carrying out a bombing, targeting the CEO at the conference is 'targeted, precise and doesn't risk innocents,' adding that it would bring light to the event and the 'greed' of its attendees.
He also appears to reference the Unabomber, Ted Kaczynski, calling such attacks 'counter-productive' because they would lose public support.
'Normies categorize him as an insane serial killer, focus on the act/atrocities themselves, and dismiss his ideas,' Mangione writes. 'And most importantly—- by committing indiscriminate atrocities he becomes a monster, which makes his ideas those of a monster, no matter how true. He crosses the line from revolutionary anarchist to terrorist-the worst thing a person can be.'
Mangione's intentions to target the insurance industry were made clear by the writings, which prosecutors say prove that he committed first-degree murder in furtherance of terrorism, the Wednesday filing states. UnitedHealthcare became a symbol of the health insurance industry that Mangione aimed to abolish, prosecutors said.
He was not insured by UnitedHealthcare from 2014 to 2024, prosecutors say, but at the time of his arrest, Mangione allegedly had a handwritten notebook that expressed 'hostility toward the health insurance industry and wealthy executives in particular,' according to a federal complaint.
'Having no business relationship with them, he chose UHC solely because they were the largest health insurance company and one of the country's largest companies by market cap,' the new filing said.
Notably, three 9mm shell casings from the crime scene had the words 'delay,' 'deny' and 'depose' written on them, the NYPD has said, an apparent nod to a 2010 book critiquing insurance industry tactics.
Mangione hoped the alleged killing would intimidate health insurance employees, cause the public to focus on greed in the health insurance industry and prevent investors and financial analysts from investing in the industry, according to the filing.
The killing of the husband and father of two struck fear in C-suites across the country, as an NYPD intelligence report obtained by CNN warned online rhetoric could 'signal an elevated threat facing executives in the near-term.'
Mangione inspired some individuals to partake in a 'broader campaign of threats of violence' against UnitedHealthcare employees and other health insurance workers, the document says.
In the aftermath of Thompson's killing, threats had been aimed at other UnitedHealthcare executives and employees also reported feeling unsafe, prosecutors said.
UnitedHealthcare doctors sending out denial letters to customers feared for their safety, requesting that they not be required to sign their names to the letters, prosecutors said. Some physicians quit their jobs out of fear of retribution.
The company advised employees not to wear company branded clothes, and online threats prompted it to pull pictures of senior executives from its website, the filing states.
Meanwhile, the company's call center received a slew of death threats, the filing said. 'You are gonna hang,' one caller said. 'That means that the killing of Brian Thompson was just a start. There are a lot more that are gonna be taken out. The only question is whether you're gonna be their collateral damage when its done or not.'
Police were hired to protect the company's headquarters in Minnesota. Threats were also made to employees at the company's New York City office.
Forty company executives received personal security, with one executive who received threats dying her hair and moving into another home out of fear for her safety, according to the filing.
Other health insurance executives, including Emblem Health's CEO, were also targeted. Posters were put up outside the company's headquarters with the CEO's picture that read 'Health Care CEOs should not feel safe. Deny, Defend Depose.'
The killing 'demonstrated his concerted effort to broadcast his message of ideological intimidation as broadly and loudly as possible,' prosecutors said.
CNN's Kara Scannell, Zoe Sottile, Lauren del Valle and Michelle Watson contributed to this report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
13 minutes ago
- CNN
Three Rivers Mall, Kelso: Teen arrested in alleged mass shooting plot at a Washington state mall, officials say
An Oregon teen has been arrested in connection with an alleged mass shooting plot targeting the Three Rivers Mall in Kelso, in southwestern Washington, officials said. The suspect, whose identity has not been disclosed due to their age, allegedly planned to detonate a chlorine bomb to create chaos and panic before shooting fleeing patrons exiting a movie theater, the FBI Portland Field Office said in a statement. The Columbia County, Oregon, Sheriff's Office arrested the suspect on May 22, the FBI said. 'This plot was as serious as it gets,' FBI Portland Special Agent in Charge Doug Olson said in the statement. 'An alarming amount of indicators of a cogent path to violence were met – at no point in this plan did it seem like the suspect wouldn't follow through with their plans,' the statement said. The FBI was first alerted to the plot on May 19 and identified the suspect the following day. According to authorities, the juvenile, a resident of Columbia County, subscribed to a 'nihilistic violent extremist ideology' and shared their plans in online chats. Guy Edward Bartkus, the man accused of bombing a Palm Springs fertility clinic last month also had nihilistic ideations, FBI officials said at the time. According to FBI research of past violent actors, nihilistic ideation refers to a 'preoccupation with themes of violence, hopelessness, despair, pessimism, hatred, isolation, loneliness, or an 'end-of-the-world' philosophy,' said retired senior FBI profiler Dr. Mary Ellen O'Toole. 'Nihilistic ideation is a very pessimistic view of the world.' Officials placed the suspect in Oregon under court-authorized surveillance before the arrest, citing evidence of both intent and means to carry out the attack. The FBI said the plan included details on the use of an improvised explosive device, a specific route through the mall, and a sequence of actions culminating in the suspect's planned suicide at the mall. The Columbia County district attorney is prosecuting the case. Authorities are urging the public to report suspicious behavior and encouraging parents 'to engage with their children and have an open dialogue about their online activity.' CNN has reached out to Columbia County officials for further details.
Medscape
25 minutes ago
- Medscape
Which Tx Combo Is Best for HER2+ Breast Cancer?
The combination of trastuzumab deruxtecan (Enhertu) with pertuzumab (Perjeta) as a first-line treatment for HER2-positive advanced metastatic breast cancer has been shown to reduce the risk for disease progression or death by more than the current standard-of-care treatment. Sara Tolaney, MD, MPH Sara Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, presented this finding and other interim results of the phase 3 DESTINY-Breast09 study, at the American Society of Clinical Oncology (ASCO) 2025 annual meeting in Chicago. 'Trastuzumab deruxtecan, or T-DXd, in combination with pertuzumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, with a 44% reduction in the risk of disease progression or death when compared to a taxane, trastuzumab, and pertuzumab (THP),' said Tolaney, during her presentation. New First-line Standard? Similar results were observed across all patient subgroups, with no new safety signals, Tolaney said. 'These data suggest that T-DXd and pertuzumab may represent a new first-line standard of care for patients with metastatic HER2-positive breast cancer,' she said. The study randomized 1157 patients to three treatment groups: T-DXd 5.4 mg/kg every three weeks plus placebo, T-DXd-pertuzumab, or a taxane plus trastuzumab with pertuzumab (THP). The interim study readout includes only data from the T-DXd-pertuzumab and the taxane plus trastuzumab with pertuzumab groups. Pertuzumab + T-Dxd or Standard of Care? Median progression-free survival (PFS) was 40.7 months in the T-DXd-pertuzumab patients and 26.9 months in the taxane plus trastuzumab with pertuzumab patients ( P < .00001). Tolaney explained that the study was designed to have an interim analysis for PFS after approximately 399 events across the three arms with at least 277 events for comparison. At the time of the interim analysis, she said, only the TDX-pertuzumab and THP groups met the criteria for superiority, a P -value < .00043, which was not met for the comparison of T-DXd plus placebo to THP. The T-DXd-placebo arm remains blinded until the final progression-free survival analysis, Tolaney said. Twenty-one percent of the patients in the T-DXd-pertuzumab arm had discontinued T-DXd due to adverse events, Tolaney said; 9% of patients elected to continue with trastuzumab and pertuzumab after they discontinued T-DXd. Among hormone receptor-positive patients, 13.5% in the T-DXd-pertuzumab group and 38% in the THP group elected to add endocrine treatment. At the data cutoff, 46% of the T-DXd-pertuzumab patients and 33% of those in the THP group remained on study treatment. Median follow-up duration was 29 months. The treatment effect of T-DXd-pertuzumab became evident early in the study, Tolaney said. Six months after starting treatment, 7% of the T-DXd-pertuzumab group vs 12% of the THP group had progressed. The gap continued to widen over time, she said. 'With 26% of patients still on steady treatment with T-DXd and pertuzumab, it suggests that this median is likely to evolve with further follow-up,' she said. Objective response rates were also higher with T-DXd–pertuzumab, 86% vs 79% with THP, Tolaney said. 'The complete response rate for T-DXd and pertuzumab was 15%, which was almost double what was seen with THP (8.5%),' she said. Response duration was also longer with T-DXd-pertuzumab, with 73% remaining in response at 24 months vs 55% in the THP arm. 'Overall survival data are very immature at this timepoint with just 16% of survival events seen, but you can see that there is an early trend favoring T-DXd plus pertuzumab with a hazard ratio of 0.84,' she said. A similar number of patients in both groups had serious treatment-emergent adverse events: 27% for T-DXd-pertuzumab and 25.1% for THP, which Tolaney said, was consistent with the known toxicity profiles of both agents, with no new toxicities identified. The median duration of treatment in the DESTINY-Breast09 study was 21 months. 'A Pivotal Advancement?' Rebecca Dent, MD, deputy CEO at the National Cancer Center Singapore, called the DESTINY-Breast09 results 'a pivotal advancement in the treatment of HER2-positive metastatic breast cancer that is both clinically and statistically significant.' Rebecca Dent, MD HER2-positive metastatic breast cancer was once considered a 'death sentence,' Dent said at a press conference, but now patients can survive on therapy for years, which presents its own challenges. Regarding the T-DXd-plus-pertuzumab regimen, Dent said, 'Is this for all patients at the beginning of their treatment for metastatic disease?' The truth of the matter is we don't know.' Having better biomarkers would provide answers, she said, but for patients with extensive disease with central nervous system metastasis, pertuzumab in combination with other agents 'is clearly your first-line choice.' How to best sequence therapies is another challenge emerging with these evolving treatment regimens, Dent added. 'And then I think finally we do have to appreciate that there are toxicities: One in terms of quality of life but also cost toxicity,' she said. Which Therapeutic Regimen Costs More? Tolaney acknowledged the cost implications of adding pertuzumab to T-DXd, in an interview with Medscape Medical News . 'But I would also note,' Tolaney said, 'that the standard-of-care arm does involve getting continued trastuzumab and pertuzumab therapy.' In the PATINA study, which added palbociclib (Ibrance) to standard maintenance therapy in patients with HER2-positive metastatic breast cancer, the cost profile was similar to those of the treatments used in the newer trial, Tolaney said. 'You are looking at substantial continued cost because we're continuing to suppress the HER2 pathway for years in these patients,' she said. AstraZeneca and Daiichi Sankyo funded the study. Tolaney reported financial relationships with ADi, Ambrx, Artios Biopharmaceuticals, Arvinas, AstraZeneca, Bayer, BeiGene, Bicycle Therapeutics, BioNTech, Blueprint Medicines, Bristol Myers Squibb, Circle Pharma, Cullinan Oncology, Daiichi Sankyo, eFFECTOR Therapeutics, Eisai, Exelixis, Genentech, Gilead Sciences, Hengrui Pharmaceutical (USA), Immunomedics/Gilead, Incyte, Jazz Pharmaceuticals, Johnson & Johnson, Launch Therapeutics, Lilly, Menarini Group, Merck, Mersana, NanoString Technologies, Natera, Novartis, OncoPep, Pfizer, Reveal Genomics, Sanofi, Seagen, Sumitovant Biopharma, Summit Therapeutics, Systimmune, Tango Therapeutics, Zentalis, Zuellig Pharma, and Zymeworks. Dent reported having financial relationships with AstraZeneca, Daiichi Sankyo/Astra Zeneca, DKSH, Eisai, Gilead Sciences, Merck Sharpe and Dohme, Novartis, Pfizer, and Roche.
CNN
33 minutes ago
- CNN
Live updates: Sean ‘Diddy' Combs trial continues with investigation into Cassie Ventura relationship
Update: Date: Title: Former attorney for Trump breaks down legal risks of courtroom conduct in latest CNN podcast Content: It's been a busy fourth week of Sean 'Diddy' Combs' federal trial: a woman dangling from a 17th floor balcony, the threat of Combs being removed from the courtroom for nodding to the jury, and a new alleged victim on the stand known as 'Jane.' On the latest episode of 'Trial By Jury: Diddy' — a podcast from CNN's Laura Coates — Joe Tacopina, former attorney for President Donald Trump and the rapper A$AP Rocky, breaks down the legal risks of the testimony and the courtroom conduct. Listen here. Update: Date: Title: Here's what we learned in court yesterday Content: A judge rebuked Sean 'Diddy' Combs for his behavior in court, and a woman using the pseudonym 'Jane' alleged that Combs pressured her to have sex with other men as part of her testimony at the hip-hop mogul's federal criminal trial yesterday. Here's what we learned in testimony yesterday: Judge warns Combs for gesturing to jury Jane describes 'hotel nights' with Combs Jane says she became 'frustrated' Defense uses receipts to undermine alleged balcony assault
